

*Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation. With the publication of this announcement, this information is now considered to be in the public domain.*

**30 September 2025**

**Provexis plc**  
('Provexis' or the 'Company')

**Delay in publication of annual accounts**  
**Trading update**  
**Temporary suspension from trading on AIM**

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that the audit of its financial statements for the year ended 31 March 2025 (the 'Accounts') is ongoing and will not be completed by today, 30 September 2025, being the deadline under Rule 19 of the AIM Rules for Companies.

The Company continues to work with its new auditors, RPG Crouch Chapman LLP, in their first year as the Group's auditor, to ensure that the audit of the Accounts is completed as soon as possible. The Company currently anticipates that the audit will be completed, and Accounts released by mid-October 2025.

For the year ended 31 March 2025 the Company confirms on an unaudited basis that it expects to report:

- sales of £1.29m, a 61% increase year on year which reflects strong demand from existing and new customers for Fruitflow;
- an underlying operating loss of £278k (year ended 31 March 2024: £469k), an improvement of £191k year on year. The year ended 31 March 2025 included nine months of the royalty payable to dsm-firmenich at the second year rate to 31 December 2024, and three months of the royalty payable at the lower third year rate to 31 March 2025. The royalty will decrease further, and at a higher rate of year-on-year decrease, from 1 January 2026, and it will wholly cease to be payable on 31 December 2026; and
- cash at bank at 31 March 2025 of £708k, and net assets at 31 March 2025 in excess of £750k.

The Company also confirms that in the six months ended 30 September 2025:

- it has sold all of the remaining Fruitflow II SD inventory which it purchased from dsm-firmenich ('DSM') in 2023 and 2024;
- it has undertaken a new production run of Fruitflow II SD which has just been completed by the Company's outsourced supply chain partners for Fruitflow. The Company expects to receive delivery of the new batch of Fruitflow II SD in October 2025, two months later than originally planned, due in part to some significant personnel changes at an outsourced supply chain partner. The Company will pay for this new production run on delivery in October, from its existing cash resources; and
- it expects in due course to report total sales for the six months ended 30 September 2025 in excess of £350,000, and it currently expects to sell several hundred thousand pounds of Fruitflow II SD in the coming quarter ended 31 December 2025, initially supported by some existing, outstanding purchase orders.

The Company is dealing with numerous sales enquiries from existing and new customers for further direct sales of Fruitflow in 2026 and beyond, in which favourable context the Company is now planning with its outsourced supply chain partners to undertake at least one further production run of Fruitflow II SD in the next twelve months.

It is currently envisaged that the Company will hold its Annual General Meeting at the offices of Allenby Capital Limited, 5th Floor, 5 St Helen's Place, London EC3A 6AB at 12:30pm on 21 November 2025.

The delay to the publication of the Accounts means that trading in the Company's ordinary shares on AIM will be temporarily suspended with effect from 7:30 AM on 1 October 2025, pending publication of the Accounts. Suspension from trading is expected to be lifted with the publication of the Accounts.

For further information please contact:

Provexis plc  
Ian Ford, CEO  
Dawson Buck, Chairman

Tel: 07490 391888  
[enquiries@provexis.com](mailto:enquiries@provexis.com)

Allenby Capital Limited (Nominated Adviser and Broker) Tel: 020 3328 5656  
Nick Naylor / Liz Kirchner / Lauren Wright

#### Notes for editors

##### About Provexis plc

AIM quoted Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.

Fruitflow is a natural, breakthrough ingredient that helps with platelet aggregation. This helps promote normal blood flow and circulation, which in turn benefits cardiovascular health. Fruitflow helps the platelets to circulate freely and smoothly throughout your blood, without sticking to one another or to the blood vessels themselves. Freely flowing blood helps reduce stress on your cardiovascular system.

Fruitflow is a highly concentrated form of bioactives which is lycopene-free and contains over 30 known anti-platelet compounds. Published clinical studies have shown that Fruitflow works to maintain healthy blood flow in a similar way to 75mg aspirin but with a milder and reversible action; Fruitflow has a similar antiplatelet effect to a single dose of aspirin - but when taken daily, it has none of aspirin's side effects.

The science behind Fruitflow has been validated by leading peer review publications and regulatory authorities. Fruitflow is the only natural antiplatelet to have a health claim approved by the European Food Safety Authority, stating that 150mg of Fruitflow 'helps maintain normal platelet aggregation, which contributes to healthy blood flow'.

Fruitflow has a number of specific health benefits which have been reflected in separate patent filings for the use of Fruitflow in:

- mitigating exercise-induced inflammation;
- managing blood pressure;
- protecting against the adverse effects of air pollution on the body's cardiovascular system. Laboratory work has shown that Fruitflow can reduce the platelet activation caused by airborne particulate matter, such as that from diesel emissions, by approximately one third; and
- conferring health benefits in modulating the gut microbiome of humans, to include a reduction in TMAO, following the completion of a successful human study which is further detailed here [www.dsm-firmenich.com/en/businesses/health-nutrition-care/news/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html](http://www.dsm-firmenich.com/en/businesses/health-nutrition-care/news/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html).

Provexis sells a high quality dietary supplement product containing Fruitflow and Omega-3 from its website [www.fruitflowplus.com](http://www.fruitflowplus.com) on a mail order basis. The product is also available to purchase from Amazon.co.uk.

Provexis has been working with BYHEALTH, a circa £2bn listed Chinese dietary supplement business, for more than eight years to support the planned launch of a number of Fruitflow based products in the Chinese market. Clinical studies conducted in China are typically required to obtain the necessary regulatory clearances in China, and a significant investment in eight separate Fruitflow studies has been undertaken at BYHEALTH's expense. Completed studies have shown excellent results in use for Fruitflow, and they provide strong evidence for the efficacy of Fruitflow on platelet function.

The Chinese regulatory system for functional health food ingredients, such as Fruitflow, is governed by the State Administration for Market Regulation (the 'SAMR') and it is based on a defined list of permitted health function claims which brand owners are permitted to use on product labels.

In August 2023 the Company was delighted to report that BYHEALTH had submitted: i) the first application for a new permitted health function claim and ii) some related product registration applications.

The significance of these major developments for Fruitflow in China is further outlined here [www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods](http://www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods). BYHEALTH has noted that it has been working on the project since 2015, with 'tens of millions of funds' (RMB) invested by BYHEALTH in the research and development work.

Provexis was founded in 1999 and is headquartered in Reading, Berkshire. Provexis' shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

For further information, please visit [www.provexis.com](http://www.provexis.com) and [www.fruitflowplus.com](http://www.fruitflowplus.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

SUSUROBRVWUKORR